Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.41 |
| ▸ | AR | P10275 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | FASN | P49327 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29392429 | 0.83 | AR (0.42) | ARKDM4EUSP2ALDH1A1PGR | |
| SCHEMBL15536667 | 0.82 | MAOA (0.47) | ARKDM4EALDH1A1PGRLMNA | |
| SCHEMBL15535758 | 0.81 | SELL (0.38) | CNR2ARKDM4EALDH1A1KMT2A | |
| SCHEMBL29392564 | 0.80 | AR (0.42) | ARKDM4EUSP2PGRLMNA | |
| SCHEMBL15535914 | 0.79 | ERN1 (0.47) | ARKDM4EUSP2ALDH1A1PGR | |
| SCHEMBL29392561 | 0.79 | KDM4E (0.44) | ARKDM4EUSP2PGRLMNA | |
| SCHEMBL15536114 | 0.78 | AR (0.45) | ARKDM4EALDH1A1PGRLMNA | |
| SCHEMBL16969071 | 0.78 | ERN1 (0.46) | ARKDM4EUSP2ALDH1A1PGR | |
| SCHEMBL29391740 | 0.78 | HSD17B1 (0.42) | ARPGRLMNAMAPK1HSD17B10 | |
| SCHEMBL29391998 | 0.78 | KDM4E (0.43) | ARKDM4EUSP2ALDH1A1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220047540-A1 | CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS | ORION CORP (FI) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220047540-A1 | CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS | COMT, PNMT, HNMT | CNR2 3371/4885AR 1837/4885KDM4E 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.